Abstract
Previously, we showed that the P3 domain of the Escherichia coli ribonuclease P ribozyme can be truncated and replaced in vitro. In this study, we prepared a P3-replaced variant of the E. coli ribozyme that has HIV TAR sequence as the engineered P3 domain. The mutant ribozyme demonstrated the ribonuclease P activity and was inhibited in the presence of the HIV tat protein fragment. Our results showed that the P3 domain of this enzyme can be engineered, and addition of some heterologous protein subunits can also be done to this domain.
Original language | English |
---|---|
Pages (from-to) | 343-344 |
Number of pages | 2 |
Journal | Nucleic acids symposium series (2004) |
Issue number | 49 |
Publication status | Published - 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)